About the Centre of molecular inflammation research (CEMIR)

CEMIR research group, March 2, 2016. Photo: Jacob S. Jensen

The vision of the Centre of Molecular Inflammation Research (CEMIR) is to lay the foundation for identifying new therapeutic targets and developing new diagnostic tools for inflammatory diseases.

This will happen through an integrated 10-year programme of research and research training in molecular innate immune responses. CEMIR was established on 10. June 2013 as a Centre of Excellence (SFF) appointed by the Research Council of Norway.


Inflammation is a host response that is triggered by infection and tissue injury. A controlled inflammatory response is needed to fight infections and to heal wounds, but it can become detrimental if it is dysregulated as seen in chronic inflammatory disorders like cardiovascular disease, diabetes, Alzheimer's disease, inflammatory bowel disease, obesity, cancer, and others.

Drawing on major recent advances in the field of innate immunity and cell biology, CEMIR's research programme will detail the molecular and cell biological principles for initiation and regulation of inflammatory responses through the use of basic research, in vitro- and in vivo models and unique biobanks. The localisation of CEMIR in an integrated University hospital environment will facilitate translational research on human disease.

Host institution

Centre of Molecular Inflammation Research (CEMIR) is hosted by the Faculty of Medicine and Health Sciences (MH) at the Norwegian University of Science and Technology (NTNU).

The CEMIR activities are located in Kunnskapssenteret at Campus Øya and St. Olavs hospital. CEMIR is a centre at the Department of Cancer Research and Molecular Medicine, NTNU.


  • Björn Gustafsson, Dean, Faculty of Medicine and Health Sciences (MH), NTNU
  • Magne Børset, Head, Department of Cancer Research and Molecular Medicine (IKMM), NTNU
  • Terje Robert Meisler, Vice Dean for Education, Faculty of Information Technology and Electrical Engineering (IE), NTNU
  • Petter Aadahl, Research Director, St. Olavs Hospital
  • Anne Borg, Dean at the Faculty of Natural Sciences (NV), NTNU

Scientific Advisory Board (SAB)


CEMIR works in close cooperation with St. Olavs hospital and Central Norway Regional Health Authority, Helse Midt-Norge